Showing 1761-1770 of 2038 results for "".
- Researchers Explain How Reading Might Contribute to Myopiahttps://modernod.com/news/researchers-explain-how-reading-might-contribute-to-myopia/2481520/Researchers at the State University of New York (SUNY) are publishing a paper explaining how reading might contribute to myopia. In a paper that will be published in the Journal of Vision, scientists demonstrate that the images formed by our eyes during reading lack
- Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Diseasehttps://modernod.com/news/kuria-therapeutics-completes-fda-pre-ind-consultation-for-topical-nrf2-activator-for-corneal-endothelial-disease/2481475/Kuria Therapeutics has announced it has completed a pre-investigational new drug (IND) interaction with the FDA and received positive feedback on its development program for KTX-1161 for corneal endothelial disease. KTX-1161 is a topical ophthalmic solution formulation of SCO-
- Ace Vision Group Appoints Cristos Ifantides, MD, as Director, Clinical Applications Developmenthttps://modernod.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/Ace Vision Group (AVG) announced the appointment of Cristos Ifantides, MD, MBA, as Director, Clinical Applications Development, effective immediately. In his new role, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Bruder Healthcare Now Exclusive Licensor of "The Dry Eye Drink"https://modernod.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/Bruder Healthcare, which is part of Hilco Vision, announced an exclusive licensing agreement with Dry Eye Drink LLC, the manufacturer of a portfolio of dry eye products and drink mixes formulated to provide relief for US adults suffering from symptoms of dry eye disease.
- Roche Names Teresa Graham Head of its Pharma Businesshttps://modernod.com/news/roche-names-teresa-graham-head-of-its-pharma-business/2481379/Teresa Graham, former Genentech executive and current Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO of Roche Pharmaceuticals, based in Basel, Switzerland, effective March 2023. She will also become a member of the Corporate Executive Committee.</
- Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defectshttps://modernod.com/news/trefoil-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-tthx1114-for-treatment-of-corneal-epithelial-defects/2481356/Trefoil Therapeutics announced dosing of the first patient in its phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects. The phase 1 study is designed to assess t
- Nanotechnology May Improve Gene Therapy for Blindnesshttps://modernod.com/news/nanotechnology-may-improve-gene-therapy-for-blindness/2481350/Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness, according to the National Eye Institute. A collaborative team of researchers with Oregon Health & Science University and Oreg
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di